Nedaplatin
- Generic Name
- Nedaplatin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C2H8N2O3Pt
- CAS Number
- 95734-82-0
- Unique Ingredient Identifier
- 8UQ3W6JXAN
- Background
Nedaplatin is a second generation platinum analog . It is less nephrotoxic than Cisplatin but has proven equally effective. It was approved for use in Japan in 1995.
- Indication
Used in the treatment of non-small cell lung cancer, small cell lung cancer, oesophygeal cancer, and head and neck cancers .
- Associated Conditions
- -
- Associated Therapies
- -
Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC
- First Posted Date
- 2018-04-19
- Last Posted Date
- 2018-05-11
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 632
- Registration Number
- NCT03503136
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Study of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-11-16
- Last Posted Date
- 2020-05-15
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 12
- Registration Number
- NCT02964455
- Locations
- 🇨🇳
Hui Liu, Guangzhou, Guangdong, China
Liposomal Paclitaxel Combined Nedaplatin in Treatment of Advanced or Recurrent Esophageal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-08-10
- Last Posted Date
- 2016-08-10
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 72
- Registration Number
- NCT02861690
- Locations
- 🇨🇳
Medical Oncology,Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma
- First Posted Date
- 2016-08-08
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 120
- Registration Number
- NCT02858206
- Locations
- 🇨🇳
Zefen Xiao, Beijing, Beijing, China
Pelvic External Combined With 252-Cf Neutron Intracavitary Radiotherapy With or Without Platinum in Treating Advanced Cervical Cancer
- First Posted Date
- 2016-07-18
- Last Posted Date
- 2016-07-18
- Lead Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- Target Recruit Count
- 200
- Registration Number
- NCT02835404
- Locations
- 🇨🇳
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, Chongqing, China
Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas
- Conditions
- Interventions
- First Posted Date
- 2016-05-18
- Last Posted Date
- 2024-07-30
- Target Recruit Count
- 107
- Registration Number
- NCT02776163
- Locations
- 🇨🇳
Shanghai ninth people's hospital, Shanghai, Shanghai, China
Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-12-31
- Last Posted Date
- 2015-12-31
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 488
- Registration Number
- NCT02643407
- Locations
- 🇨🇳
Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China
A Phase II Clinical Trial of Chemotherapy With or Without Endostar® Continuous Intravenous Infusion in Refractory NPC
- Conditions
- Interventions
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2017-12-22
- Lead Sponsor
- Yun-fei Xia
- Target Recruit Count
- 328
- Registration Number
- NCT02590133
- Locations
- 🇨🇳
Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China
The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-09-02
- Last Posted Date
- 2015-09-02
- Lead Sponsor
- Changjie Huang
- Target Recruit Count
- 120
- Registration Number
- NCT02537925
- Locations
- 🇨🇳
The third Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy for Locally Advanced Esophageal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-04-29
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 80
- Registration Number
- NCT02429622
- Locations
- 🇨🇳
Zefen Xiao, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.